Form 4: OptimizeRx CFO/COO Edward Stelmakh Reports Stock and Option Grants

Edward Stelmakh, CFO/COO of OptimizeRx Corp, reports the acquisition of restricted stock units and stock options.

Summary

• Edward Stelmakh, CFO/COO of OptimizeRx Corp, filed a Form 4 detailing changes in beneficial ownership.
• On December 23, 2024, Stelmakh acquired 41,408 shares of common stock through restricted stock units and disposed of 97,295 shares.
• He also acquired stock options for 77,742 shares of common stock with an exercise price of $4.83.
• The restricted stock units vest in three equal annual installments starting December 23, 2025.
• The stock options also vest in three equal annual installments beginning December 23, 2025, and expire on December 23, 2027.
• Following these transactions, Stelmakh directly owns 77,742 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating standard compensation practices. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The grant of restricted stock units and stock options to the CFO/COO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The grants align management's interests with shareholders, potentially driving long-term value.

Key Dates